Introduction
============

The recMAGE-A3 protein has been administered intramuscularly (IM) with immunostimulant AS15 as an experimental immunotherapeutic. AS15 contains 3-O-desacyl-4\'-monophosphoryl lipid A (MPL), QS-21, CpG 7909 and liposome. This MAGE-A3/AS15 immunotherapeutic has not been studied for intradermal (ID) or subcutaneous (SC) use. A clinical trial (NCT01425749) was initiated to test the hypotheses that ID/SQ administration is safe and may induce CD4^+^and CD8^+^T cell responses to MAGE-A3.

Patients and methods
====================

Twenty-five eligible patients with resected stage IIB-IV MAGE-A3^+^melanoma were randomized to 2 arms, treated with MAGE-A3/AS15 Immunotherapeutic IM (Arm A, n = 13) or ID/SC (Arm B, n = 12). Adverse events (CTCAE 4) were recorded. Antibody (Ab) responses to MAGE-A3 protein were assessed by ELISA assay. T cell responses were assessed by flow cytometry after intracellular cytokine staining (ICS) for multifunctional CD4^+^and CD8^+^responses to overlapping MAGE-A3 peptides, assaying lymphocytes from peripheral blood (PBMC) and sentinel immunized node (SIN), after one *in vitro*stimulation.

Results
=======

In both arms, the recMAGE-A3/AS15 immunotherapeutic was well-tolerated, with only one grade 3 treatment-related adverse event (hyperglycemia, Arm B), and no grade 4 or 5 events. Grade 2 injection site reactions were observed in 10 patients in Arm A and 7 in Arm B (P \> 0.3). Ab responses were detected in all patients, most with high titers persisting at least 6 months, without difference between arms. Preliminary T cell data are that multifunctional (IFNg and TNFα) CD4^+^T cell responses to MAGE-A3 were detected in 64% of patients (54% A; 75% B; Table [1](#T1){ref-type="table"}). Multifunctional CD8^+^T cell responses were evident in 20% of patients (8% A, 33% B). CD4^+^responses were higher magnitude in SIN than in PBMC.

###### 

Multifunctional (IFNg and TNFα) T cell responses to MAGE-A3

          \% of CD4+ T cells   \% of CD8+ T cells                                  
  ------- -------------------- -------------------- ---------- --------- --------- ----------
          (90% CI)             (90% CI)                                            
          SIN                  PBMC                 Either     SIN       PBMC      Either
  Arm A   31%                  31%                  54%        0%        8%        8%
          (11, 58)             (11, 58)             (29, 78)   (0, 21)   (0, 32)   (0, 32)
  Arm B   64%                  50%                  75%        18%       25%       33%
          (35, 86)             (25, 75)             (47, 93)   (3, 47)   (7, 53)   (12, 61)
  Total   46%                  40%                  64%        8%        16%       20%
          (28, 64)             (24, 58)             (46, 80)   (2, 24)   (6, 33)   (8, 38)

Conclusion
==========

Safety profiles were comparable for ID/SC and IM administration of the MAGE-A3/AS15 immunotherapeutic, which induced high-titer Ab, multifunctional CD4^+^Th1 responses, and CD8^+^responses when administered by either route. Immune responses were more readily detected in the SIN than in PBMC. These pilot data support further investigation of ID/SC immunization with antigen plus AS15 to support Th1 CD4^+^responses and CD8^+^responses. Production of Th1 cytokines IFNg and TNFα suggests the induced CD4^+^responses may support CD8^+^T cells. Other forms of antigen (e.g.: long peptides) may further support induction of CD8^+^T cell responses in combination with AS15.
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